Boehringer Ingelheim provides terminated both scholarly studies.

Closure of the tipranavir trials TICINO and Springtime After consideration of the feasibility of achieving the enrolment targets for the SPRING twice daily in 400 racially and gender diverse HIV-positive treatment-experienced population) and TICINO trials, Boehringer Ingelheim provides terminated both scholarly studies. These trials have been stopped due to poor enrolment rather than to any protection or efficacy reasons. Both EMEA and the FDA are in agreement with the decision to prevent these trials. SPRING was made to compare the basic safety and efficacy of tipranavir/ritonavir in a varied treatment-experienced male and female population.Antidepressant drug sales plummet as patents expire and patients flee to safer alternatives The market for antidepressant drugs is usually quickly drying up as patents on long-time blockbusters like Lexapro, owned by Forest Laboratories, and Seroquel, possessed by AstraZeneca, continue steadily to expire. And because they’re unable to develop fresh multi-billion-dollar blockbuster medicines to take their areas, many drug producers are ditching the antidepressant business altogether, especially as studies continue to emerge showing that antidepressants are useless and cause even more harm than good mainly. A recent Reuters report seems to bemoan the fact that advancement of a new antidepressant drug ceased after it was discovered that the medication was ineffective.

Other articles from category "herbal medicine":

Random articles